For the year ending 2025-12-31, REGN has $40,558,700K in assets. $9,301,800K in debts. $3,118,100K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | 3,118,100 | 2,488,200 | 2,730,000 | 3,105,900 |
| Marketable securities | 5,487,100 | 6,524,300 | 8,114,800 | 4,636,400 |
| Accounts receivable, net | 5,741,100 | 6,211,900 | 5,667,300 | 5,328,700 |
| Inventories | 3,200,800 | 3,087,300 | 2,580,500 | 2,401,900 |
| Prepaid expenses and other current assets | 474,800 | 349,200 | 386,600 | 411,200 |
| Total current assets | 18,021,900 | 18,660,900 | 19,479,200 | 15,884,100 |
| Marketable securities | 10,260,600 | 8,900,100 | 5,396,500 | 6,591,800 |
| Property, plant, and equipment, net | 5,120,400 | 4,599,700 | 4,146,400 | 3,763,000 |
| Intangible assets, net | 1,257,400 | 1,148,600 | 1,038,600 | 915,500 |
| Deferred tax assets | 4,077,200 | 3,314,100 | 2,575,400 | 1,723,700 |
| Other noncurrent assets | 1,821,200 | 1,136,000 | 444,100 | 336,400 |
| Total assets | 40,558,700 | 37,759,400 | 33,080,200 | 29,214,500 |
| Accounts payable | 939,000 | 789,500 | 606,600 | 589,200 |
| Accrued expenses and other current liabilities | 2,876,400 | 2,527,100 | 2,357,900 | 2,074,200 |
| Finance lease liabilities | - | - | - | 0 |
| Deferred revenue | 553,000 | 627,700 | 458,900 | 477,900 |
| Total current liabilities | 4,368,400 | 3,944,300 | 3,423,400 | 3,141,300 |
| Long-term debt | 1,985,900 | 1,984,400 | 1,982,900 | 1,981,400 |
| Finance lease liabilities | 720,000 | 720,000 | 720,000 | 720,000 |
| Deferred revenue | 208,700 | 185,700 | 126,700 | 69,800 |
| Other noncurrent liabilities | 2,018,800 | 1,571,400 | 854,100 | 638,000 |
| Total liabilities | 9,301,800 | 8,405,800 | 7,107,100 | 6,550,500 |
| Common stock-Common Class A | 0 | 0 | 0 | 0 |
| Common stock-Common Stock | 100 | 100 | 100 | 100 |
| Additional paid-in capital | 13,995,000 | 12,855,900 | 11,354,000 | 9,949,300 |
| Retained earnings | 35,797,100 | 31,672,900 | 27,260,300 | 23,306,700 |
| Accumulated other comprehensive income (loss) | 77,500 | -7,900 | -80,900 | -238,800 |
| Treasury stock, at cost 33.7 shares in 2025 and 28.2 shares in 2024 | 18,612,800 | 15,167,400 | 12,560,400 | 10,353,300 |
| Total stockholders' equity | 31,256,900 | 29,353,600 | 25,973,100 | 22,664,000 |
| Total liabilities and stockholders' equity | 40,558,700 | 37,759,400 | 33,080,200 | 29,214,500 |
REGENERON PHARMACEUTICALS, INC. (REGN)
REGENERON PHARMACEUTICALS, INC. (REGN)